Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTOMATIX: Insulin Glargine U300 Titration with MyStar DoseCoach in T2DM
NCT02585674Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2015
- Primary completion
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of patients reaching fasting SMPG target range 90-130 mg/dL without a severe hypoglycemic episode at 16 weeks. Started Dec 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02585674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02585674.